Some major drugmakers are hesitant to participate in the Trump administration's faster review program for new drugs because of potential legal risks.[original content] The European Medicines Agency (EMA) has issued a favorable opinion on a higher dose of Wegovy (semaglutide 7.2 mg).[1][4] In the STEP UP study, obese patients without diabetes lost an average of 20.7% of their body weight after 72 weeks of treatment, with one in three losing 25% or more.[1][4] The STEP UP trial was a randomized, double-blind, placebo-controlled study comparing semaglutide 7.2 mg with 2.4 mg and placebo in lifestyle modification.[1][4] The STEP UP T2D trial of 512 patients with obesity and type 2 diabetes demonstrated the efficacy of 7.2 mg over placebo in weight loss at 72 weeks.[1][4] A Swiss Re study states that widespread use of GLP-1 drugs such as Ozempic or Wegovy could reduce mortality by 6.4% in the US and 5.1% in the UK by 2045.[2] In Phase 3 trials of Eli Lilly's tirzepatide, participants lost 16.0 to 22.5% of their weight after 72 weeks, with more than 96% achieving at least a 5% loss.[3]